TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06361537: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angi

Sponsor: Octapharma · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 124 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT06361537 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06361537 Rescue Dossier →